AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
LENZ Therapeutics' Partner Lotus Pharma Seeks Approval for Presbyopia Treatment in South Korea
ByAinvest
Tuesday, Dec 2, 2025 8:42 am ET1min read
LENZ Therapeutics' partner Lotus Pharmaceutical has submitted a New Drug Application to the Ministry of Food and Drug Safety in South Korea seeking approval for VIZZ, a treatment for presbyopia. The application is backed by positive data from Phase 3 trials conducted in the US. The approval would mark the first regulatory submission for VIZZ, with potential milestone payments and royalties for LENZ Therapeutics. Presbyopia is the age-related decline in near vision affecting millions worldwide.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet